Clinical Trial Update: To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE) [Phase 3]

View source ↗

Summary

This Phase 3 clinical trial update describes evaluating long-term safety and tolerability of acoramidis in newly diagnosed transthyretin amyloid cardiomyopathy …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloidosis with Cardiomyopathy

Drugs mentioned

• Acoramidis (acoramidis)

Snippet

Sponsor: Eidos Therapeutics, a BridgeBio company | Conditions: Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial | Phase 3 | Status: NOT_YET_RECRUITING